Astrazeneca Plc · LSE:AZN
Astrazeneca — 34th J.P. Morgan Healthcare Conference 2016
28 slides from Astrazeneca's conference presentation, Jan 12, 2016
Slide 1: AstraZeneca
AstraZeneca Pascal Soriot, Executive Director, Chief Executive Officer 34th J.P. Morgan Healthcare Conference, San Francisco 12 January 2016
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, pe
Slide 3: Key messages
Key messages Strategy implementation on track - started second phase of the Journey Late-stage pipeline progressing ahead of plans • Science-driven, collaborative culture driving increased R&D productivity • Steady newsflow expected in 2016 Accelerating return to growth and ambition to become
Slide 4: On track to deliver long-term goals
On track to deliver long-term goals >$45bn1 in 2023 2012-2014 2015-2017 2018+ Building strong Delivering on return Sustainable delivery foundations to growth and growth 1. Target is at constant exchange rates (2013) 4
Slide 5: 3 strategic priorities launched in 2013
3 strategic priorities launched in 2013 Achieve 1 Return 2 Be a great 3 scientific to growth place to work leadership 5
Slide 6: Late-stage pipeline volume well ahead of plan
Late-stage pipeline volume well ahead of plan Targeted Achieved/On track to achieve Phase III and Registration NME Phase III and Registration NME pipeline volume (#) pipeline volume (#) 15 13 11 9-10 8 6 6 2012 2013E 2016E 2012 2013 2014 2015 Source: AstraZeneca Annual Report 6
Slide 7: 2015: Delivering the late-stage pipeline
2015: Delivering the late-stage pipeline cediranib Iressa Zurampic Tagrisso submission (EU) approval (US) positive Advisory approval (US) Committee (US) saxa/dapa Zurampic submission (EU) CAZ AVI saxa/dapa Brilinta submission submission (EU) Complete Response ACS, post-MI Letter (US) submission (JP)
Slide 8: Key late-stage new medicines and lifecycle programmes
Key late-stage new medicines and lifecycle programmes Respiratory, Inflammation Cardiovascular & Oncology Other & Autoimmunity Metabolic Disease Phase III Under review Phase III Under review Phase III Under review Under review PT010 PT003 roxadustat ZS-9 selumetinib cediranib CAZ AVI LAMA/LABA/ICS L
Slide 9: Tagrisso exemplifies progress being made
Tagrisso exemplifies progress being made • First treatment approved for patients with a very specific form of NSCLC • Fastest development journey in the company’s history: 32 months from first-in-man to approval • Fastest shipment time: 6 hours from approval • Reinforces ambition in Oncology to deli
Slide 10: Several products in the pipeline have large potential
Several products in the pipeline have large potential Tagrisso durva + treme Lung cancer Multiple cancers Lynparza acalabrutinib1 Ovarian, other cancers Blood cancers ZS-9 roxadustat Hyperkalaemia Anaemia benralizumab PT010 Severe asthma, COPD COPD, asthma anifrolumab Lupus (SLE) 1. Pending completi
Slide 11: Biotech units: Driving the 'next wave' of innovation
Biotech units: Driving the ‘next wave’ of innovation “Next-wave” Long-term delivery sustainability Around 30 projects Advancing potentially currently in Phase I will transformative platforms deliver “next wave” of such as oligonucleotides, molecules to late stage novel proteins, cancer vaccines and
Slide 12: Scientific leadership and innovation power
Scientific leadership and innovation power 5521 397 205 No. of publications 248 310 147 37 2 2010 2015 2015 2010 High impact publications >15 impact factor Publications >5 impact factor Publications <5 impact factor 1 Includes accepted publications 12
Slide 13: Cambridge UK research centre catalyst for innovation
Cambridge UK research centre catalyst for innovation Scientific collaboration is a key driver behind the move Laboratory of School of Clinical Molecular Biology Cambridge Institute Medicine Planned R&D Centre and Corporate HQ building Site of planned Energy Centre Addenbrooke’s Hospital and R&D Enab
Slide 14: 3 strategic priorities launched in 2013
3 strategic priorities launched in 2013 Achieve 1 Return 2 Be a great 3 scientific to growth place to work leadership 14
Slide 15: Achieve Scientific Leadership
Achieve Scientific Leadership R&D in three therapy areas (TAs) and across key platforms Respiratory, Cardiovascular & Inflammation & Oncology Metabolic Disease Autoimmunity Infection & Vaccines Neuroscience TAs Opportunity-driven Small Protein Biologics Immuno-therapies Devices molecules engineering
Slide 16: Growth Platforms: Progress across all areas
Growth Platforms: Progress across all areas YTD 2015 % Q3 2015 % $m change $m change Growth Platforms 10,354 +10 3,455 +8 Respiratory 3,698 +8 1,230 +7 Brilinta/Brilique 445 +44 170 +48 Diabetes 1,638 +26 577 +17 Emerging Markets 4,394 +12 1,427 +10 Japan 1,479 +3 502 +6 Product Sales at actual exch
Slide 17: Growth Platforms: Delivering revenue goals
Growth Platforms: Delivering revenue goals Product Sales $ million 57% 53% 14,000 49% Respiratory 12,000 41% Brilinta/Brilique 10,000 Diabetes 8,000 Emerging Markets 6,000 Japan 4,000 2,000 0 FY 2012 FY 2013 FY 2014 3Q 2015 Product Sales at actual exchange rates. Growth rates at CER 17
Slide 18: Building a durable presence in Emerging Markets
Building a durable presence in Emerging Markets: 3rd fastest-growing pharma MNC; ~$5.8bn in 2014 Europe China 25% of sales 9% of sales US 39% of sales Japan 9% of sales Emerging Markets Rest of World (ex-China) Established 14% of sales (ex-Japan) 5% of sales Note: FY sales 2014 MNC = Multi-National
Slide 19: 3 strategic priorities launched in 2013
3 strategic priorities launched in 2013 Achieve 1 Return 2 Be a great 3 scientific to growth place to work leadership 19
Slide 20: Be a Great Place to Work
Be a Great Place to Work Gothenburg, Sweden Cambridge, UK Gaithersburg, USA Strategic R&D Centre NEW Global R&D Centre & Strategic R&D Centre Corporate Headquarter Specialty Products Group 20
Slide 21: High Engagement
High Engagement Employee engagement in line with Awards for overall work environment best-performing companies 85% 86% Employee Belief in the strategy engagement (18% increase) (8% increase) 88% Scientific and patient orientation (12% increase) 21
Slide 22: The market is recognising progress…
The market is recognising progress… Market now agrees with Investor Day in 2013 March 2013 December 2015 2018 2018 Change Consensus estimate Consensus estimate Growth Platforms & Other 20.4 Growth Platforms & Other 21.4 +5% Pipeline 1.1 Pipeline 3.7 +236% Total revenue 21.5 Total revenue 25.1 +17% S
Slide 23: …and some fully agree with the long-term targets
…and some fully agree with the long-term targets 2023 Total Revenue target of >$45bn (CER 20131) $m Total Revenue forecasts 45,000 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0 FY15E FY16E 6% FY17E FY18E FY19E FY20E FY21E FY22E FY23E Analyst 1 BoA Analyst 2 Citi 1 The >$45bn 2023 revenue
Slide 24: Pipeline value unlocked
Unlocking significant pipeline value in the mid term Major regulatory submissions of new medicines & new uses CAZ AVI Serious infections (EU) cediranib acalabrutinib1 moxetumomab Ovarian cancer (EU) Blood cancer Leukaemia Pipeline value unlocked Tagrisso durvalumab selumetinib durva + treme Lung can
Slide 25: Total Shareholder Return (TSR) since 1 January 2013
Total Shareholder Return (TSR) since 1 January 2013 AstraZeneca has outperformed the largest FTSE 100 companies1 Index TSR AstraZeneca vs. FTSE 100 200 190 180 +83% 170 160 150 140 130 120 +18% 110 100 31/12/2012 31/12/2013 31/12/2014 31/12/2015 AZN FTSE 100 1 TSR between 1 Jan 2013 and 31 Dec 2015.
Slide 26: Key messages
Key messages Strategy implementation on track - started second phase of the Journey Late-stage pipeline progressing ahead of plans • Science-driven, collaborative culture driving increased R&D productivity • Steady newsflow expected in 2016 Accelerating return to growth and ambition to become
Slide 27: Key newsflow through 2016
Key newsflow through 2016 Regulatory approvals Key regulatory submissions Key data readouts H1 2016 • brodalumab - psoriasis (US, EU) H1 2016 • PT003 - COPD (US) • ZS-9 - hyperkalaemia (EU) • benralizumab - severe asthma • ZS-9 - hyperkalaemia (US) • Brilinta/Brilique - stroke • Tagrisso - lung canc
Slide 28: AstraZeneca
AstraZeneca Pascal Soriot, Executive Director, Chief Executive Officer 34th J.P. Morgan Healthcare Conference, San Francisco 12 January 2016
AstraZeneca — 34th J.P. Morgan Healthcare Conference 2016 on 6ix